What one share of Insmed holds
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.
Insmed’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.30 |
|---|---|
| Profit | −$4.08 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | −$3.76 |
| Cash and investments | $5.32 |
| Debt | $2.59 |
| Book value | $3.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $0.82 | $9.31 | $0.00 | −$0.87 | — | $9.75 |
| 2010 | $0.52 | −$0.49 | $0.00 | −$0.58 | — | $12.26 |
| 2011 | $0.19 | −$2.95 | $0.04 | −$1.34 | — | $5.41 |
| 2012 | $0.00 | −$1.56 | $0.01 | −$1.18 | — | $3.84 |
| 2013 | $0.33 | −$1.60 | $0.02 | −$1.36 | — | $3.66 |
| 2014 | — | −$1.84 | $0.12 | −$1.62 | — | $3.74 |
| 2015 | $0.00 | −$2.02 | $0.06 | −$1.78 | — | $5.04 |
| 2016 | $0.00 | −$2.85 | $0.07 | −$2.44 | — | $2.49 |
| 2017 | $0.00 | −$2.89 | $0.05 | −$2.44 | — | $4.71 |
| 2018 | $0.13 | −$4.22 | $0.17 | −$3.53 | — | $2.69 |
| 2019 | $1.61 | −$3.01 | $0.50 | −$3.46 | — | $2.92 |
| 2020 | $1.68 | −$3.01 | $0.06 | −$2.31 | — | $2.68 |
| 2021 | $1.68 | −$3.88 | $0.07 | −$3.31 | — | $3.46 |
| 2022 | $1.99 | −$3.91 | $0.08 | −$3.33 | — | $0.65 |
| 2023 | $2.17 | −$5.34 | $0.09 | −$3.91 | — | −$2.24 |
| 2024 | $2.22 | −$5.57 | $0.13 | −$4.30 | — | $1.59 |
| 2025 | $3.05 | −$6.42 | $0.16 | −$4.86 | — | $3.45 |
Common questions about Insmed
How much does one share of Insmed earn?
Over the last 12 months, Insmed lost $4.08 for each share on $5.30 of sales.
Does Insmed pay a dividend?
Insmed didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Insmed’s book value per share?
Insmed’s book value is $3.47 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Insmed have?
Each share of Insmed has $5.32 of cash and investments and $2.59 of debt, as of June 30, 2026.
What is Insmed’s free cash flow per share?
−$3.76 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Insmed bought back shares?
Insmed’s share count rose about 1466% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.